Key result
Candesartan cilexetil suppresses progressive aortic dilatation in Marfan syndrome mice, unlike neutral antagonist candesartan-7H.
Why the study?
Does inverse agonist activity of ARBs prevent progressive aortic dilatation in a Marfan syndrome mouse model?
Does inverse agonist activity of ARBs prevent progressive aortic dilatation in a Marfan syndrome mouse model?
Answers are grounded in this paper and cite their sources.
Inverse agonist activity of ARBs is crucial for preventing mechanical stress-induced AT1 receptor activation and aortic aneurysm progression in Marfan syndrome, independent of blood pressure lowering.
BACKGROUND: Marfan syndrome is an inherited disorder caused by FBN1 gene mutations, which can lead to thoracic aortic aneurysm and dissection. Selective AT 1 (angiotensin II type 1) receptor blockade is a preventive option against Marfan syndrome aortopathy, and recent clinical studies demonstrated that the inhibitory effect of an ARB (AT 1 receptor blocker) losartan on aortic aneurysm growth is equivalent to that of β-blockers. At present, several ARBs are clinically available, and they have drug-specific differences in pharmacological properties. Especially, inverse agonism of ARBs has potential benefits for cardiovascular protection, but its impact on Marfan syndrome aortopathy remains poorly understood. METHODS: Candesartan-7H is a candesartan derivative that lacks the carboxyl group critical for inverse agonist activity and works as a neutral antagonist for the AT 1 receptor. Candesartan cilexetil (1 mg/kg per day), candesartan-7H (1 or 20 mg/kg per day), or vehicle was administered to Fbn1 C1041G/+ mice, and aortic dilatation was analyzed using echocardiography, histological staining, and in situ MMP (matrix metalloproteinase) assay. Activation of TGF-β (transforming growth factor β) signaling and mechanosensitive signaling was studied using Western blot and immunohistochemical analysis. RESULTS: Candesartan cilexetil (1 mg/kg per day) and candesartan-7H (20 mg/kg per day) lowered blood pressures equally in Fbn1 C1041G/+ mice. Progressive dilatation of the aorta in association with aortic wall thickening, degeneration of elastic fibers, deposition of collagen, MMP activation, and TGF-β signaling activation in Fbn1 C1041G/+ mice was significantly suppressed by treatment with candesartan cilexetil (1 mg/kg per day), but not by candesartan-7H, even at 20 mg/kg per day. In addition, candesartan cilexetil, but not candesartan-7H, suppressed activation of mechanosensitive signaling involving focal adhesion kinase, p38 mitogen-activated protein kinase, and early growth response-1 in the ascending aorta of Fbn1 C1041G/+ mice. CONCLUSIONS: Our findings support a crucial role of inverse agonist activity of ARB for the prevention of mechanical stress-induced AT 1 receptor activation and aortic aneurysm progression in Marfan syndrome mice.
No takes yet. Share an insight, caveat, or question.
Yagi et al. (2025) studied Marfan syndrome aortopathy. Candesartan cilexetil vs. Candesartan-7H or vehicle was evaluated on Progressive dilatation of the aorta and associated pathological changes. Candesartan cilexetil significantly suppressed progressive aortic dilatation in Marfan syndrome mice, whereas the neutral antagonist candesartan-7H did not.
Synapse has enriched 10 related papers. Consider them for comparative context: